

DAFTAR PUSTAKA

1. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. *JAMA Netw Open*. 2021 May 10;4(5):e218401.
2. Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. *Pregnancy Hypertens*. 2019 Jan;15:23–31.
3. Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2019. Jakarta; 2020.
4. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2019. Padang; 2020 Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2019. Padang; 2020.
5. Tsurayya, Pertiwi Familia. Karakteristik dan Outcome Pasien Preeklampsia Berat di RSUP Dr. M. Djamil Padang Tahun 2020. Universitas Andalas. 2022.
6. Verlohren S, Dröge LA. The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. *Am J Obstet Gynecol*. 2022 Feb;226(2):S1048–58.
7. Nirupama R, Divyashree S, Janhavi P, Muthukumar SP, Ravindra PV. Preeclampsia: Pathophysiology and management. *J Gynecol Obstet Hum Reprod*. 2021 Feb;50(2):101975.
8. Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. *Biomolecules*. 2020 Jun 24;10(6):953.
9. Helmo FR, Lopes AMM, Carneiro ACDM, Campos CG, Silva PB, Dos Reis Monteiro MLG, et al. Angiogenic and antiangiogenic factors in preeclampsia. *Pathol - Res Pract*. 2018 Jan;214(1):7–14.
10. Gebara N, Correia Y, Wang K, Bussolati B. Angiogenic Properties of Placenta-Derived Extracellular Vesicles in Normal Pregnancy and in Preeclampsia. *Int J Mol Sci*. 2021 May 20;22(10):5402.

11. Rana S, Burke SD, Karumanchi SA. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. *Am J Obstet Gynecol*. 2022 Feb;226(2):S1019–34.
12. Pant V, Yadav BK, Sharma J. A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia. *BMC Pregnancy Childbirth*. 2019 Dec;19(1):266.
13. Kornacki J, Wirstlein P, Wender-Ozegowska E. Markers of Endothelial Injury and Dysfunction in Early- and Late-Onset Preeclampsia. *Life*. 2020 Oct 14;10(10):239.
14. Stepan H, Hund M, Andraczek T. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome. *Hypertension*. 2020 Apr;75(4):918–26.
15. Robertson SA. Preventing Preeclampsia by Silencing Soluble Flt-1? *N Engl J Med*. 2019 Mar 14;380(11):1080–2.
16. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia—Pathophysiology and Clinical Presentations. *J Am Coll Cardiol*. 2020 Oct;76(14):1690–702.
17. Dröge LA, Perschel FH, Stütz N, Gafron A, Frank L, Busjahn A, et al. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. *Hypertension*. 2021 Feb;77(2):461–71.
18. Palmer K, Tong S, Kaitu'u-Lino T. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. *MHR Basic Sci Reprod Med*. 2017;23(2):69–78.
19. Lou W zhen, Jiang F, Hu J, Chen X xu, Song Y na, Zhou X ya, et al. Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women. *Dis Markers*. 2019 Jul 16;2019:1–7.
20. Mayer-Pickel K, Stern C, Eberhard K, Lang U, Cervar-Zivkovic M. Changes of platelet count throughout pregnancy in women with antiphospholipid syndrome. *J Reprod Immunol*. 2019 Nov;136:102612.

21. Haldar B, Barui G. Study of coagulation profile and platelet indices in pregnancy induced hypertension with special reference to preeclamptic and eclamptic patients. 2020;
22. Liao D, Chen L, Li Q, Liu G, Wang W, Li J, et al. Predictive Value of the Peripheral Blood Parameters for Preeclampsia. *Clin Lab*. 2022;68(3).
23. Walle M, Gelaw Y, Getu F, Asrie F, Getaneh Z. Preeclampsia has an association with both platelet count and mean platelet volume: A systematic review and meta-analysis. Cox D, editor. *PLOS ONE*. 2022 Sep 14;17(9):e0274398.
24. Thalor N, Singh K, Pujani M, Chauhan V, Agarwal C, Ahuja R. A correlation between platelet indices and preeclampsia. *Hematol Transfus Cell Ther*. 2019 Apr;41(2):129–33.
25. Gupta A, Gaur BS, Mishra KB, Dubey I. A comparison of platelet count in severe preeclampsia, mild preeclampsia and normal pregnancy. *Int J Res Med Sci*. 2018 Jan 24;6(2):671
26. Kumar A, Singh S. Correlation of Preeclampsia with Platelet Indices. *Int J Toxicol Pharmacol Res*.
27. Singh A, Varma R. Role of Platelet Distribution Width (PDW) and Plateletcrit in the Assessment of Nonthrombocytopenic Preeclampsia and Eclampsia. *J Obstet Gynecol India*. 2018 Aug;68(4):289–93.
28. Major HD, Campbell RA, Silver RM, Branch DW, Weyrich AS. Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. *Am J Obstet Gynecol*. 2014;210(6):547.e1-547.e5477. doi:10.1016/j.ajog.2014.01.024
29. Bouter AR, Duvekot JJ. Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia. *Pregnancy Hypertens*. 2020;19:206–11.
30. Lai J, Syngelaki A, Nicolaides KH, Von Dadelszen P, Magee LA. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. *Am J Obstet Gynecol*. 2021 May;224(5):518.e1-518.e11.

31. Magley M, Hinson MR. Eclampsia. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554392/>
32. Gomathy E, Akurati L, Radhika K. Early onset and late onset preeclampsia-maternal and perinatal outcomes in a rural tertiary health center. *Int J Reprod Contracept Obstet Gynecol*. 2018;7(6):2266–70.
33. Sriyanti R, Mose JC, Masrul M, Suharti N. The difference in maternal serum hypoxia-inducible factors-1 α levels between early onset and late-onset preeclampsia. *Open Access Maced J Med Sci*. 2019;7(13):2133.
34. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. *Circ Res*. 2019;124(7):1094–112.
35. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. *Bmj*. 2019;366.
36. Bernardes TP, Mol BW, Ravelli AC, van den Berg P, Boezen HM, Groen H. Early and late onset pre-eclampsia and small for gestational age risk in subsequent pregnancies. *PLoS One*. 2020;15(3):e0230483.
37. Roberts JM. The perplexing pregnancy disorder preeclampsia: what next? *Physiol Genomics*. 2018;50(6):459–67.
38. Robillard PY, Dekker G, Chaouat G, Elliot MG, Scioscia M. High incidence of early onset preeclampsia is probably the rule and not the exception worldwide. 20th anniversary of the reunion workshop. A summary. *J Reprod Immunol*. 2019;133:30–6.
39. Macedo TC, Montagna E, Trevisan CM, Zaia V, de Oliveira R, Barbosa CP, et al. Prevalence of preeclampsia and eclampsia in adolescent pregnancy: A systematic review and meta-analysis of 291,247 adolescents worldwide since 1969. *Eur J Obstet Gynecol Reprod Biol*. 2020;248:177–86.
40. Vousden N, Lawley E, Seed PT, et al. Incidence of eclampsia and related complications across 10 low- and middle-resource geographical regions: Secondary analysis of a cluster randomised controlled trial. *PLoS Med*. 2019;16(3):e1002775. Published 2019 Mar 29. doi:10.1371/journal.pmed.1002775

41. Putri TJ. Perbandingan usia ibu pada kejadian preeklamsia dan eklamsia di RSUP Dr. M. Djamil Padang tahun 2022. Skripsi. Padang: Fakultas Kedokteran Universitas Andalas. 2023
42. Sert ZS. The role of serum netrin-1 level in the detection of early-onset preeclampsia. *Eur J Obstet Gynecol Reprod Biol.* 2022;270:164–8.
43. Raia-Barjat T, Edebiri O, Ni Ainle F. Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy. *Front Cardiovasc Med.* 2022 Mar 7;9:856923.
44. Fillion A, Guerby P, Menzies D, Lachance C, Comeau MP, Bussi eres MC, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). *Hypertens Pregnancy.* 2021;40(1):56–62.
45. Kholin A, Khodzhaeva Z, Gus A. Pathological placentation and prediction of preeclampsia and intrauterine growth restriction in the first trimester. *Akusherstvo Ginekol.* 2018;5:12–9.
46. Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaitong P, Jaovisidha A, et al. The etiology of preeclampsia. *Am J Obstet Gynecol.* 2022;226(2):S844–66.
47. Gerasimova EM, Fedotov SA, Kachkin DV, Vashukova ES, Glotov AS, Chernoff YO, et al. Protein misfolding during pregnancy: new approaches to preeclampsia diagnostics. *Int J Mol Sci.* 2019;20(24):6183.
48. Ali Z, Khaliq S, Zaki S, Ahmad HU, Lone KP. Altered expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, and Soluble Fms-like Tyrosine Kinase-1 in peripheral blood mononuclear cells from normal and preeclamptic pregnancies. *Chin J Physiol.* 2019;62(3):117.
49. Suzuki H, Hirashima C, Nagayama S, Takahashi K, Yamamoto T, Matsubara S, et al. Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at < 32 weeks compared with \geq 32 weeks. *Pregnancy Hypertens.* 2018;12:96–103.
50. Mayer-Pickel K, Stern C, Eberhard K, Lang U, Obermayer-Pietsch B, Cervar-Zivkovic M. Comparison of mean platelet volume (MPV) and sFlt-

- 1/PIGF ratio as predictive markers for preeclampsia. *J Matern Fetal Neonatal Med.* 2021;34(9):1407–14.
51. Stolz M, Zeisler H, Heinzl F, Binder J, Farr A. An sFlt-1: PIGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. *Pregnancy Hypertens.* 2018;11:54–60.
 52. Zhu X, Chen L, Li R. Values of serum sFlt-1, PLGF levels, and sFlt-1/PLGF ratio in diagnosis and prognosis evaluation of preeclamptic patients. *Clin Exp Hypertens.* 2020;42(7):601–7.
 53. Nikuei P, Rajaei M, Roozbeh N, Mohseni F, Poordarvishi F, Azad M, et al. Diagnostic accuracy of sFlt1/PIGF ratio as a marker for preeclampsia. *BMC Pregnancy Childbirth.* 2020;20(1):1–6.
 54. Herraiz I, Llorba E, Verlohren S, Galindo A, Spanish Group for the Study of Angiogenic Markers in Preeclampsia. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PIGF ratio in singleton pregnancies. *Fetal Diagn Ther.* 2018;43(2):81–9.
 55. Dymara-Konopka W, Laskowska M, Błażewicz A. Angiogenic imbalance as a contributor of preeclampsia. *Curr Pharm Biotechnol.* 2018;19(10):797–815.
 56. Nunes PR, Romao-Veiga M, Medeiros Borges VT, Matias ML, Ribeiro VR, Araujo Costa RA, et al. Association between adverse maternal clinical outcomes and imbalance of cytokines and angiogenic factors in preterm preeclampsia. *Pregnancy Hypertens.* 2018 Oct;13:S91.
 57. Ngene NC, Moodley J. Role of angiogenic factors in the pathogenesis and management of pre-eclampsia. *Int J Gynecol Obstet.* 2018;141(1):5–13.
 58. Eddy AC, Bidwell GL, George EM. Pro-angiogenic therapeutics for preeclampsia. *Biol Sex Differ.* 2018;9(1):1–11.
 59. lie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res.* 2020 Jul;32(7):1195–8.
 60. Jayaram A, Buhimschi IA, Aldasoqi H, Hartwig J, Owens T, Elam GL, et al. Who said differentiating preeclampsia from COVID-19 infection was easy? *Pregnancy Hypertens.* 2021;26:8–10.

61. Docheva N, Arenas G, Nieman KM, Lopes-Perdigao J, Yeo KTJ, Rana S. Angiogenic biomarkers for risk stratification in women with preeclampsia. *Clin Chem.* 2022;68(6):771–81.
62. Armaly Z, Jadaon JE, Jabbour A, Abassi ZA. Preeclampsia: novel mechanisms and potential therapeutic approaches. *Front Physiol.* 2018;9:973.
63. Flint EJ, Cerdeira AS, Redman CW, Vatish M. The role of angiogenic factors in the management of preeclampsia. *Acta Obstet Gynecol Scand.* 2019;98(6):700–7.
64. Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. *Int J Mol Sci.* 2019;20(17):4246.
65. Deshpande JS, Sundrani DP, Sahay AS, Gupte SA, Joshi SR. Unravelling the potential of angiogenic factors for the early prediction of preeclampsia. *Hypertens Res.* 2021;44(7):756–69.
66. Tong W, Giussani DA. Preeclampsia link to gestational hypoxia. *J Dev Orig Health Dis.* 2019 Jun;10(3):322–33.
67. Haire G, Egan K, Parmar K, McKinnon T, Monteith C, O'Connor H, et al. Alterations in fibrin formation and fibrinolysis in early onset-preeclampsia: Association with disease severity. *Eur J Obstet Gynecol Reprod Biol.* 2019 Oct;241:19–23.
68. Li L, Yang H, Chen P, Xin T, Zhou Q, Wei D, et al. Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment. *Front Bioeng Biotechnol.* 2020 Feb 11;8:64.
69. Verlohren S, Brennecke SP, Galindo A, Karumanchi SA, Mirkovic LB, Schlembach D, et al. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. *Pregnancy Hypertens.* 2022 Mar;27:42–50.
70. Peguero A, Fernandez-Blanco L, Mazarico E, Benitez L, Youssef L, Crispi F, et al. Added prognostic value of longitudinal changes of angiogenic factors in early-onset severe preeclampsia: a prospective cohort study. 2020;

71. Veisani Y, Jenabi E, Delpisheh A, Khazaei S. Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis. *Int J Reprod Biomed.* 2019 Mar 7;17(1):1.
72. Abbas AM, Fikry EM, Mostafa TS, Shaltout AS, El-Baz MAH. Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study. *Hypertens Pregnancy.* 2018 Jul 3;37(3):137–43.
73. Moser, Guettler, Forstner, Gauster. Maternal Platelets of the Human Placenta: Friend or Foe? *Int J Mol Sci.* 2019 Nov 11;20(22):5639.
74. Temur M, Taşgöz FN, Çift T, Serpim G, Üstünyurt E. Role of platelet indices in prediction of preeclampsia. *Ginekol Pol.* 2021 Nov 30;92(11):792–6.
75. Fountain JH, Lappin SL. Physiology, Platelet. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 21]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK470328/>
76. Prameswari, A., Iskandar, A., Wafi, M.. Jumlah Rerata Trombosit Dan Plateletcrit (MPV dan PCT) Di Rs Dr. Saiful Anwar Malang. *Majalah Kesehatan FKUB.* 2018; 5(3): 153-159.
77. Kiswari, R. 2014. *Hematologi dan Transfusi.* Erlangga. Jakarta
78. Sahin, M., Duru, N.S., Eleveli, M., Civilibal, M. Assessment of platelet parameters in pneumonia. *J Pediatr Inf.* 2017; 11(3):e106–e112
79. Sachdev, R., Tiwari, A.K., Goel, S., Raina, V., Sethi, M. Establishing biological reference intervals for new platelet parameters (immature platelet fraction, high immature plate let fraction, platelet distribution width , platelet large-cell ratio, platelet-X, plateletcrit, and platelet distribution width) and their correlation with each other. *Microbiol J Pathol India.* 2014;57:231-5.
80. Zhang, S., Cui, Y.L., Diao, M.Y., Chen, D.C., Lin, Z.F. Penggunaan indeks trombosit untuk menentukan keparahan penyakit dan memprediksi prognosis pada pasien sakit kritis. *Chin Med J.* 2015;128:2012-18. <http://dx.doi.org/10.4103/0366-6999.161346>
81. Takeyama, H., Mizushima, T., Iijima, H., Shinichiro, S., Uemura, M., Nishimura, J. Platelet activation markers are associated with Crohn's disease activity in patients with low Creactive protein. *Dig Dis Sci.* 2015;60:3418- 23.

82. Nugraha, G. 2017. Panduan Pemeriksaan Laboratorium Hematologi Dasar, CV Trans Info Media.
83. Thachil, J. Platelets in inflammatory disorders: a pathophysiological and clinical perspective. *Semin Thromb Hemost* 2015;41:572-81.
84. Velez, J.L. 2018. Is mean platelet volume a predictor of death in septic patients? Literature review. *Revista Medica Herediana* [Internet]. 12Jul.2018
85. Noris, P., Melazzini, F., Balduini, C.L. New roles for mean platelet volume measurement in the clinical practice?. *Platelet*. 2016: 607 - 612
86. Quispe Pari, J.F., Gonzales Zamora, J.A., Munive Dionisio, J., Castro Contreras, C., Villar Astete, A., Kong Paravicino, C., et al.. Mean Platelet Volume as a Predictor of COVID-19 Severity: A Prospective Cohort Study in the Highlands of Peru. *Diseases*. 2022;10(22).
87. Guclu, E., Kocayigit, H., Okan, H.D., Erkorkmaz, U., Yurumez, Y., Yaylac, S., et al. Effect of COVID-19 on platelet count and its indices. *Revista da Associacao Medica Brasileira*. 2020;66(8): 1122–1127.
88. Gao., Yanxia., Liu., Yi., Yu., Xuezhong., Guo., et al.. The Impact of Various Platelet Indices as Prognostic Markers of Septic Shock. *PloS one*. 2014
89. Budak, YU., Polat, M., Huysal, K.. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review. *Biochemia medica*, 2016; 6(2): 178–193.
90. Chandrashekar, V. Plateletcrit sebagai alat skrining untuk mendeteksi kelainan kuantitatif trombosit. *J Hematol*. 2013 ;2:22– 6. <http://dx.doi.org/10.4021/jh70w>.
91. Astuti, D. Nilai Indeks Trombosit Sebagai Kontrol Kualitas Komponen Konsentrat Trombosit. *Meditory : The Journal of Medical Laboratory*. 2021; 8. 85-94. DOI 10.33992/m.v8i2.1238.
92. Pogorzelska, K., Krętońska, A., Krawczuk, R.M., Sawicka, Z.M. 2020. Characteristics of platelet indices and their prognostic significance in selected medical condition - a systematic review. *Adv Med Sci*. 2020 Sep;65(2):310-315.

93. Mannaerts D, Heyvaert S, De Cordt C, Macken C, Loos C, Jacquemyn Y. Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? *J Matern Fetal Neonatal Med.* 2019 May 3;32(9):1412–9.
94. Duan Z, Li C, Leung WT, Wu J, Wang M, Ying C, et al. Alterations of Several Serum Parameters Are Associated with Preeclampsia and May Be Potential Markers for the Assessment of PE Severity. *Dis Markers.* 2020 Jan 14;2020:1–7.
95. Lin SS, Wang CR, Wei DM, Lu JH, Chen XJ, Chen QZ, et al. Incremental predictive value of platelet parameters for preeclampsia: results from a large prospective cohort study. *BMC Pregnancy Childbirth.* 2023 May 26;23(1):387.
96. Umezulike BS, Anikwe CC, Nnachi OC, Iwe BCA, Ifemelumma CC, Dimejesi IBO. Correlation of platelet parameters with adverse maternal and neonatal outcomes in severe preeclampsia: A case-control study. *Heliyon.* 2021 Dec;7(12):e08484.
97. Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, McIntosh JJ. Vascular Dysfunction in Preeclampsia. *Cells.* 2021 Nov 6;10(11):3055.
98. Moraes D, Milioni C, Vieira CF, Parera EA, Silva BD, Baron MV, et al. Immature Platelet Fraction and Thrombin Generation: Preeclampsia Biomarkers. *Rev Bras Ginecol E Obstetrícia RBGO Gynecol Obstet.* 2022 Aug;44(08):771–5.
99. Kahhale S, Francisco RPV, Zugaib M. Endothelial Mechanisms in Preeclampsia. In: *Endothelium and Cardiovascular Diseases* [Internet]. Elsevier; 2018 [cited 2023 Jun 21]. p. 655–64. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780128123485000453>
100. Shaikh N, Nahid S, Ummunnisa F, Fatima I, Hilani M, Gul A, et al. Preeclampsia: From Etiopathology to Organ Dysfunction. In: Abduljabbar H, editor. *Preeclampsia* [Internet]. IntechOpen; 2022 [cited 2023 Jun 21]. Available from: <https://www.intechopen.com/chapters/79809>
101. Han C, Huang P, Lyu M, Dong J. Oxidative Stress and Preeclampsia-Associated Prothrombotic State. *Antioxidants.* 2020 Nov 17;9(11):1139.

102. Stanek J. Placental pathology varies in hypertensive conditions of pregnancy. *Virchows Arch.* 2018 Mar;472(3):415–23.
103. Bellos I, Fitrou G, Pergialiotis V, Papantoniou N, Daskalakis G. Mean platelet volume values in preeclampsia: A systematic review and meta-analysis. *Pregnancy Hypertens.* 2018 Jul;13:174–80.
104. Sachan R, Patel M, Vandana, Sachan P, Shyam R. Role of platelet count and mean platelet volume and red cell distribution width in the prediction of preeclampsia in early pregnancy. *J Fam Med Prim Care.* 2021;10(2):838.
105. Cui L, Shu C, Liu Z, Tong W, Cui M, Wei C, et al. Serum protein marker panel for predicting preeclampsia. *Pregnancy Hypertens.* 2018 Oct;14:279–85.
106. Schlembach D, Hund M, Wolf C, Vatish M. Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review. *Pregnancy Hypertens.* 2019 Jul;17:28–35.
107. Reddy SG, Rajendra Prasad CSB. Significance of platelet indices as severity marker in nonthrombocytopenic preeclampsia cases. *J Lab Physicians.* 2019 Jul;11(03):186–91.
108. Tesfay F, Negash M, Alemu J, Yahya M, Teklu G, Yibrah M, et al. Role of platelet parameters in early detection and prediction of severity of preeclampsia: A comparative cross-sectional study at Ayder comprehensive specialized and Mekelle general hospitals, Mekelle, Tigray, Ethiopia. Mastrolia SA, editor. *PLOS ONE.* 2019 Nov 21;14(11):e0225536.
109. Çintesun E, Çintesun FNI, Ezveci H, Akyürek F, Çelik Ç. Systemic inflammatory response markers in preeclampsia. *J Lab Physicians.* 2018 Jul;10(03):316–9.
110. Li Y, Sun L, Zheng X, Liu J, Zheng R, Lv Y. The clinical value of platelet parameters combined with sFlt-1/PlGF in predicting preeclampsia. *Ann Palliat Med.* 2021;10(7):7619-7626. doi:10.21037/apm-21-1244
111. Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. *BMC Pregnancy Childbirth.* 2013 Dec;13(1):110.
112. Santosa dkk. Karakteristik Pasien Preeklampsia dan Eklamsia di RSUD Dr. T.C. Hillers Maumere. *Jurnal Kedokteran Brawijaya.* 2024; 33(1):17-22

113. Lombo GE, Wagey F, Mamengko LS. Karakteristik Ibu Hamil dengan Preeklampsia di RSUP Prof Dr. R. D. Kandou Manado. *Jurnal Kedokteran Klinik*. 2017; 1(3): 9-16.
114. Bdolah Y, Elchalal U, Natanson-Yaron S, et al. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. *Hypertens Pregnancy*. 2014;33(2):250-259. doi:10.3109/10641955.2013.858745
115. Wójtowicz A, Zembala-Szczerba M, Babczyk D, Kołodziejczyk-Pietruszka M, Lewaczyńska O, Huras H. Early- and Late-Onset Preeclampsia: A Comprehensive Cohort Study of Laboratory and Clinical Findings according to the New ISHHP Criteria. *Int J Hypertens*. 2019;2019:4108271. Published 2019 Sep 17. doi:10.1155/2019/4108271
116. Garrido-Giménez C, Cruz-Lemini M, Álvarez FV, et al. Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers. *J Clin Med*. 2023;12(2):431. Published 2023 Jan 5. doi:10.3390/jcm12020431
117. Kosinska-Kaczynska K, Zgliczynska M, Kozlowski S, Wicherek L. Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia-A Systematic Review. *J Clin Med*. 2020;9(1):183. Published 2020 Jan 9. doi:10.3390/jcm9010183
118. Kevin Agastya Duarsa, A.A.N. Jaya Kusuma, Endang Sri Widiyanti, I Wayan Megadhana, Putu Doster Mahayasa, Ryan Saktika Mulyana. High Serum Ratio of Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) to Placental Growth Factor (PlGF) and High Level of Low-Density Lipoprotein (LDL) as Risk Factors of Preeclampsia, *Journal Health Sains*. 2023; 4(5).
119. Zeisler H, Llorca E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. 2016;374(1):13-22. doi:10.1056/NEJMoa1414838
120. Woldeamanuel GG, Tlaye KG, Wu L, Poon LC, Wang CC. Platelet count in preeclampsia: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. 2023;5(7):100979. doi:10.1016/j.ajogmf.2023.100979

121. Bawore SG, Adissu W, Niguse B, Larebo YM, Ermolo NA, Gedefaw L. A pattern of platelet indices as a potential marker for prediction of pre-eclampsia among pregnant women attending a Tertiary Hospital, Ethiopia: A case-control study. *PLoS ONE* 2021; 16(11): e0259543.
122. Hayuningsih C, Lismayanti L, Tjandrawati A. Comparison of Thrombocyte Indices and Immature Platelet between Preeclampsia and Normal Pregnancy. *Indonesian J. Clin. Pathol. Med. Lab.* [Internet]. 2023 Nov. 3 [cited 2024 Jul. 14];30(1):54-9.
123. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. *Hippokratia*. 2010;14(1):28-32.

